Ashley McCormick highlights the ESETT study in this April Trial of the Week.

Ashley McCormick joins to discuss the April Trial of the Week “Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus” the ESETT study, published in NEJM in 2019.

We set the scene describing PK/PD considerations with anti-seizure medications (ASM), discussed if any of these agents are considered a standard of care, and then reviewed research published by the two investigator teams involved in the ESETT study: the NETT and PECARN groups.

Then Ashley and I do a deep dive in the ESETT trial itself. Were benzodiazepines given at the right dose and in a timely fashion? Did the 75kg dose cap influence results? How does this seizure cessation % compare to other studies? Where did this dosing scheme come from? Trial Fun Facts!

Before discussing where we are now after the ESETT publication. What are medication safety considerations in a mixed adult/pediatric ED? Why is this considered such a practice-changing article? What drugs would we include if we re-designed this trial today?

That and so much more in this Trial of the Week episode.

esett-trial-of-the-week-references Download